Industry update tracker: April 2026
A monthly index of company press releases and announcements shaping the real-world data (RWD), real-world evidence (RWE) and health technology assessment (HTA) landscape.
Atropos Health implements industry-leading evidence review process to ensure quality and accuracy of evidence generation at scale
Atropos Health, the pioneer in translating real-world clinical data into personalized RWE for clinical decision-making, announced a scientific, multi-layered process for content review for novel evidence studies in Alexandria, the Atropos Evidence Library. The review process establishes the standard for the healthcare industry with a rigorous methodology for the vetting of novel evidence studies, ensuring that the evidence produced and presented in Alexandria is transparent, reliable, accurate, and actionable. Doing so expands the amount of quality and accurate evidence available for clinicians, and ultimately means clinicians get more evidence-based answers they can trust.
Atropos Health creates world’s largest body of medical evidence, Alexandria®, for clinical decision support and LLM training to improve patient, life science, and medical outcomes
Atropos Health also announced the availability of the largest source of novel medical content – with over 33M artifacts of evidence generated by a high-throughput, standardized observational evidence-creation workflow. Alexandria®, the Atropos Evidence™ Library, is slated to grow to two billion pEBFs by the end of 2026, exceeding all known medical evidence by 100x in volume. This library will enable the entire healthcare ecosystem – clinicians, researchers, life science partners, and others – to generate precise answers to complex medical questions quickly and improve patient and medical outcomes based on content not available anywhere else.
Briya hits 120M patient journeys milestone to accelerate AI-driven medical research
Briya, the health AI technology company redefining healthcare research, announced its global data network has expanded to cover over 120 million patient records. By unifying this massive RWD repository with the Briya AIRE™ research engine, Briya is delivering a scalable solution to address the industry's need for diverse, high-fidelity patient representation to advance medical innovation and personalized medicine.
Flatiron Health publishes first peer-reviewed validation framework for AI-extracted real-world oncology data in Journal of Clinical Oncology
Flatiron Health announced the publication of the Validation of Accuracy for LLM/ML-Extracted Information and Data (VALID) framework in the Journal of Clinical Oncology Clinical Cancer Informatics. The framework represents the first and most comprehensive, peer-reviewed approach to evaluating the quality and reliability of RWD extracted by LLMs and ML, setting a methodological benchmark for data integrity in oncology research.
Folia Health launches app-based study to unlock novel RWE of symptom burden and unmet need for patients and caregivers in CIDP
Folia Health announced a collaboration with argenx to launch a first-of-its-kind, at-home observational RWE initiative supporting individuals living with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). The study represents the first RWD program designed to capture the at-home experiences of individuals with CIDP and their caregivers. Designed in partnership with patients and caregivers, the initiative leverages Folia’s home-reported outcomes (HROs) platform, enabling participants to select and track the symptoms that matter most to them while documenting their individualized treatment plans. Over time, the platform captures symptom severity, treatment utilization, and other aspects of daily disease management directly from patients over an initial six-month period.
Folia Health launches “BRAVE-PWS” study to better understand the real-world experience of Prader-Willi syndrome caregivers
Folia Health also announced the launch of Burden and Real-world Assessment of Caregiver Voice and Experiences in Prader-Willi syndrome (BRAVE-PWS), a fully remote observational study, sponsored by Soleno Therapeutics, designed to better understand the real-world experience of caregivers supporting individuals with Prader-Willi syndrome (PWS). The study will use Folia’s app-based platform to collect HROs and longitudinal caregiver-reported data over six months, helping researchers characterize the day-to-day experience associated with PWS and identify the factors that most affect caregiver well-being and household functioning.
Kakao Healthcare, Sanofi partner to harness medical data for AI solutions
Kakao Healthcare has signed a memorandum of understanding with Sanofi-Aventis Korea to jointly conduct RWE research and develop artificial intelligence (AI) solutions using medical data. The companies said they will jointly conduct RWE studies using healthcare data, while developing and advancing AI models through federated learning.
Labcorp introduces AI-powered RWD platform with AWS and Datavant to accelerate Alzheimer’s research
Labcorp, a global leader of innovative and comprehensive laboratory services, announced a new AI-powered RWD platform, designed to help researchers and biopharmaceutical companies analyze Alzheimer's disease-related data faster. Developed with Amazon Web Services (AWS) and Datavant, the platform provides access to large, diverse datasets and advanced analytics – using deidentified, privacy-protected healthcare data – designed to accelerate scientific discovery, shorten drug development timelines and improve identification of patients for clinical trial recruitment. The platform enables researchers, biopharma companies, payors and contract research organizations to generate insights in minutes that previously required months of intensive data mining.
Ledidi and NordicRWE partner to advance hybrid RWE studies and pragmatic trials across the Nordics
Ledidi AS and NordicRWE AS have entered a strategic partnership to develop and conduct hybrid RWE studies and pragmatic clinical trials across the Nordic region. The partnership combines Ledidi's regulatory-grade platform for structured clinical data capture with NordicRWE's expertise in epidemiology, biostatistics and registry-based research. It is open to pharmaceutical, biotech, medtech and academic research organisations.
Navidence and Trio Health announce strategic partnership to deliver deeper, more precise RWE for life sciences
Navidence, a technology company helping healthcare and life sciences organizations design and assess the use of RWD in clinical research, announced a strategic partnership with Trio Health, a leader in EMR data transformation and real-world patient insights. Together, the two companies will deliver more precise, fit-for-purpose RWE to biopharmaceutical companies, CROs, and research organizations across the product lifecycle.
Panalgo and Navidence partner to bring clinical intelligence to every real-world data query
Panalgo, a Norstella company, and Navidence announced a strategic partnership that embeds Navidence’s validated patient definitions directly into Panalgo’s Instant Health Data (IHD) platform. The collaboration addresses one of the most persistent challenges in RWD analytics, defining diseases and therapies consistently and accurately, by making clinically reviewed phenotype definitions natively available within the analytics workflow.
Paradigm Health launches SPIRE to accelerate late-phase clinical evidence generation
Paradigm Health announced SPIRE – Scalable Platform for Integrated Research & Evidence – a new model for post-approval and late-stage clinical studies designed to help sponsors generate prospective clinical evidence faster, more predictably, and with greater real-world representativeness. SPIRE is built as a full-scale alternative to traditional post-approval study models. By combining pragmatic study design, streamlined patient recruitment, and EHR-integrated data capture across a network of research-ready community and academic sites, SPIRE enables sponsors to run studies that are better aligned to routine care while reducing burden on research staff and patients.
Paradigm Health announces collaboration with the FDA to transform regulatory review of clinical trial data
Further news from Paradigm Health saw the launch of a landmark research collaboration with the US Food & Drug Administration (FDA) focused on advancing a new model to accelerate clinical trial execution and regulatory review. The new model, already operational in a Phase 2 and Phase 1b trial, uses Paradigm Health’s technology-enabled Study Conduct platform to enable real-time review by the FDA, by automating data collection and analysis, and streamlining the reporting of key safety and efficacy signals to trial sponsors and the FDA. The goal is to establish a scalable model that reduces monitoring burden, data entry, and trial costs, speeding regulatory review, improving US clinical trial efficiency, and accelerating cures to patients.
OneMedNet, Onco-Innovations and Inka Health announces collaboration aimed to accelerate potential for oncology drug development using RWD and AI
OneMedNet Corporation, a leading provider of regulatory decision-grade, AI-ready RWD, is pleased to announce that Inka Health, a wholly-owned subsidiary of Onco-Innovations Limited, has entered into a collaboration with OneMedNet, Inc., under which Onco-Innovations and Inka Health will have access to OneMedNet’s iRWD™ platform – powered by Palantir (PLTR) Foundry – providing it access to US real-world oncology data. The agreement is intended to accelerate development timelines, reduce clinical and regulatory risk, and strengthen evidence generation for Onco-Innovations’ proprietary PNKP Inhibitor Technology targeting PTEN/SHP1-deficient cancers.
PointClickCare launches study buddy, the first AI-powered research platform to deliver instant, grant submission-ready evidence from long-term care data
PointClickCare, a leading health tech company helping providers deliver exceptional care, announced the launch of Study Buddy, a first-of-its kind, AI-powered research platform designed to dramatically accelerate academic and clinical research using RWE generation from long-term care (LTC) data. Built on the industry’s largest and most longitudinal LTC dataset (deidentified in accordance with HIPAA), Study Buddy turns natural-language research questions into credible, study-ready outputs in minutes instead of months.
Tempus announces strategic collaboration with Gilead to advance oncology R&D through RWE
Tempus AI, Inc., a technology company leading the adoption of AI to advance precision medicine, announced an expanded, multi-year collaboration with Gilead Sciences, Inc. aimed at building and advancing Gilead’s oncology pipeline. To date, Gilead has leveraged Tempus’ extensive repository of de-identified multimodal data to inform a range of oncology R&D initiatives, including trial design, indication selection, biomarker strategy, health outcomes analysis and clinical RWE. The expanded agreement provides Gilead with enterprise-wide access to Tempus’ AI-driven Lens platform, unlocking access to broader datasets across multiple indications and integrating dedicated Tempus analytical services.
Thermo Fisher Scientific’s PPD clinical research business collaborates with HealthVerity to expand RWD capabilities
Thermo Fisher Scientific, the world leader in serving science, announced a strategic data collaboration with HealthVerity, a leading RWD marketplace, to enhance data-driven clinical development and evidence generation for biopharma sponsors. Through the agreement, Thermo Fisher’s PPD™ clinical research business will gain enterprise-level access to HealthVerity’s TaXOnomy® claims dataset, representing more than 270 million de-identified patient lives across the US healthcare system.
Truveta unveils Truveta Intelligence, delivering real-time insights from RWD
Truveta announced Truveta Intelligence, a new AI-powered solution that delivers real-time insights from continuously refreshed RWD, enabling life sciences, public health, and healthcare organizations to understand how patients, treatments, and outcomes are evolving in care today, and act on that information faster than ever before. The new AI-powered experience removes the time-to-evidence barrier, enabling healthcare leaders to better understand and make informed decisions based on what’s happening in care today.
Verana Health introduces world's largest real-world dataset for prostate cancer
Verana Health®, a digital health company dedicated to revolutionizing patient care and clinical research through RWD, has introduced the largest curated real-world dataset for prostate cancer in the world. The dataset offers researchers comprehensive longitudinal insights into disease detection, treatment, and outcomes for patients affected with this malignancy.
Vitaccess announces first-of-its-kind CIDP Registry and first patient enrolled in landmark patient-centered evidence platform
Vitaccess, a leader in generating science-driven RWE, announces the launch of the Vitaccess Real CIDP Registry, a first-of-its-kind patient-centered registry in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), designed to generate longitudinal insights into CIDP. The announcement coincides with the enrolment of the first patient into the registry, marking a key milestone in building a deeper understanding of the condition.
| Register for free today to become a member of The Evidence Base and receive the latest news straight to your inbox. |